Blood Loss After a Total Hip Replacement Clinical Trial
Official title:
Study ESPER: Blood-sparing During the Placement of a Total Hip Prosthesis With the Exacyl® in Patients Treated With Rivaroxaban, Phase IV
This study evaluates the efficacy of tranexamic acid versus placebo on perioperative blood loss using two dosage regimens (standard and extended) after a surgery during total hip arthroplasty in patients receiving the novel fast-acting oral anticoagulant rivaroxaban for prophylaxis of thrombosis.
In 2011, 140 000 total hip replacements were performed and bleeding remains one of the major
complications responsible for significant morbidity. This study will evaluate a new treatment
to prevent bleeding due to this surgery. Indeed, the tranexamic acid (Exacyl) will be used in
two modes of administration (standard or extended) versus placebo combined with a Rivaroxaban
treatment at a dose of 10 mg / day for 35 days.
Patients will be randomized (exacyl standard vs exacyl extended vs. placebo) and will be
followed for 3 months.
;